These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 8260370)

  • 1. Interim analyses and stopping rules in cancer clinical trials.
    Whitehead J
    Br J Cancer; 1993 Dec; 68(6):1179-85. PubMed ID: 8260370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Flexible implementations of group sequential stopping rules using constrained boundaries.
    Burington BE; Emerson SS
    Biometrics; 2003 Dec; 59(4):770-7. PubMed ID: 14969454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stopping rules, interim analyses and data monitoring committees.
    Ashby D; Machin D
    Br J Cancer; 1993 Dec; 68(6):1047-50. PubMed ID: 8260354
    [No Abstract]   [Full Text] [Related]  

  • 4. Early stopping rules and long-term follow-up in phase III trials.
    Pignon JP; Arriagada R
    Lung Cancer; 1994 Mar; 10 Suppl 1():S151-9. PubMed ID: 8087505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A simulated sequential analysis based on data from two MRC trials.
    Donaldson AN; Whitehead J; Stephens R; Machin D
    Br J Cancer; 1993 Dec; 68(6):1171-8. PubMed ID: 8260369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Data monitoring committees and interim monitoring guidelines.
    Freidlin B; Korn EL; George SL
    Control Clin Trials; 1999 Oct; 20(5):395-407. PubMed ID: 10503800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stopping randomized trials early for benefit: a protocol of the Study Of Trial Policy Of Interim Truncation-2 (STOPIT-2).
    Briel M; Lane M; Montori VM; Bassler D; Glasziou P; Malaga G; Akl EA; Ferreira-Gonzalez I; Alonso-Coello P; Urrutia G; Kunz R; Culebro CR; da Silva SA; Flynn DN; Elamin MB; Strahm B; Murad MH; Djulbegovic B; Adhikari NK; Mills EJ; Gwadry-Sridhar F; Kirpalani H; Soares HP; Abu Elnour NO; You JJ; Karanicolas PJ; Bucher HC; Lampropulos JF; Nordmann AJ; Burns KE; Mulla SM; Raatz H; Sood A; Kaur J; Bankhead CR; Mullan RJ; Nerenberg KA; Vandvik PO; Coto-Yglesias F; Schünemann H; Tuche F; Chrispim PP; Cook DJ; Lutz K; Ribic CM; Vale N; Erwin PJ; Perera R; Zhou Q; Heels-Ansdell D; Ramsay T; Walter SD; Guyatt GH
    Trials; 2009 Jul; 10():49. PubMed ID: 19580665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Designs for efficient clinical trials.
    Simon R
    Oncology (Williston Park); 1989 Jul; 3(7):43-9; discussion 51-3. PubMed ID: 2701811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma.
    Tan SB; Chung YF; Tai BC; Cheung YB; Machin D
    Control Clin Trials; 2003 Apr; 24(2):110-21. PubMed ID: 12689733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
    Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
    Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequentist evaluation of group sequential clinical trial designs.
    Emerson SS; Kittelson JM; Gillen DL
    Stat Med; 2007 Dec; 26(28):5047-80. PubMed ID: 17573678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An analysis of protocols and publications suggested that most discontinuations of clinical trials were not based on preplanned interim analyses or stopping rules.
    Stegert M; Kasenda B; von Elm E; You JJ; Blümle A; Tomonaga Y; Saccilotto R; Amstutz A; Bengough T; Briel M;
    J Clin Epidemiol; 2016 Jan; 69():152-60. PubMed ID: 26361993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A unified theory for sequential clinical trials.
    Whitehead J
    Stat Med; 1999 Sep 15-30; 18(17-18):2271-86. PubMed ID: 10474138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework.
    Blenkinsop A; Parmar MK; Choodari-Oskooei B
    Clin Trials; 2019 Apr; 16(2):132-141. PubMed ID: 30648428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Some practical aspects of the interim monitoring of clinical trials.
    Simon R
    Stat Med; 1994 Jul 15-30; 13(13-14):1401-9. PubMed ID: 7973219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Information time scales for interim analyses of randomized clinical trials.
    Freidlin B; Othus M; Korn EL
    Clin Trials; 2016 Aug; 13(4):391-9. PubMed ID: 27136947
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic survey of randomised trials that stopped early for reasons of futility.
    Walter SD; Han H; Guyatt GH; Bassler D; Bhatnagar N; Gloy V; Schandelmaier S; Briel M
    BMC Med Res Methodol; 2020 Jan; 20(1):10. PubMed ID: 31948397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing the efficiency of clinical trials in neurodegenerative disorders using group sequential trial designs.
    van Eijk RPA; Nikolakopoulos S; Ferguson TA; Liu D; Eijkemans MJC; van den Berg LH
    J Clin Epidemiol; 2018 Jun; 98():80-88. PubMed ID: 29486281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.
    Walter SD; Han H; Briel M; Guyatt GH
    Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.